Home Validate

Amount in (Lakhs)

## Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

| Sr. No. | Details of the party (listed entity /subsidiary) entering into the transaction | | Details of the counterparty | | | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | | | | Details of the loans, inter-corporate deposits, advances or investments | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | | | | | | | | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | Notes |
| Add Delete | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | Gufic Biosciences Limited | | Gufic Private Limited | | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Any other transaction | Receiving of services | 45.00 | Approved | | | 36.40 | 0.00 | 0.00 | | | | | | | | | | |
| 2 | Gufic Biosciences Limited | | Gufic Private Limited | | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Any other transaction | Reimbursement of expenses paid | 5.00 | Approved | | | 1.56 | 0.00 | 0.00 | | | | | | | | | | |
| 3 | Gufic Biosciences Limited | | Gufic Private Limited | | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Any other transaction | Lease Rental paid | 420.00 | Approved | | | 210.00 | 0.00 | 0.00 | | | | | | | | | | |
| 4 | Gufic Biosciences Limited | | Gufic Private Limited | | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Any other transaction | Interest Free Security Deposit given against Lease | | - | | | 0.00 | 350.00 | 350.00 | | | | | | | | | | |
| 5 | Gufic Biosciences Limited | | Gufic Chem Private Limited | | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Any other transaction | Lease Rental paid | 48.00 | Approved | | | 24.00 | -39.76 | 0.00 | | | | | | | | | | |
| 6 | Gufic Biosciences Limited | | Gufic Chem Private Limited | | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Any other transaction | Interest Free Security Deposit given against Lease | | - | | | 0.00 | 36.00 | 36.00 | | | | | | | | | | |
| 7 | Gufic Biosciences Limited | | Tricon Enterprises Private Limited | | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Sale of goods or services | | 50.00 | Approved | | | 10.15 | 4.01 | 8.04 | | | | | | | | | | |
| 8 | Gufic Biosciences Limited | | Gufic UK Limited | | Wholly Owned Subsidiary of the Company | Investment | | | - | | | 0.00 | 54.12 | 54.12 | | | | | | | | | | |
| 9 | Gufic Biosciences Limited | | Gufic Prime Private Limited | | Subsidiary of the Company | Investment | | | - | | | 0.00 | 0.88 | 0.88 | | | | | | | | | | |
| 10 | Gufic Biosciences Limited | | Veira Life FZE | | Wholly Owned Subsidiary of the Company | Investment | | | - | | | 47.52 | 0.00 | 47.52 | | | | | | | | | | |
| 11 | Gufic Biosciences Limited | | Mr. Jayesh P. Choksi | | Promoter, Chairman & Managing Director | Remuneration | | | Approval of Audit Committee is not required | | | 70.11 | 0.00 | 0.00 | | | | | | | | | | |
| 12 | Gufic Biosciences Limited | | Mr. Jayesh P. Choksi | | Promoter, Chairman & Managing Director | Any other transaction | Perquisites | | Approval of Audit Committee is not required | | | 0.20 | 0.00 | 0.00 | | | | | | | | | | |
| 13 | Gufic Biosciences Limited | | Mr. Pranav J Choksi | | Promoter, Chief Executive Officer & Whole Time Director | Remuneration | | | Approval of Audit Committee is not required | | | 51.24 | 0.00 | 0.00 | | | | | | | | | | |
| 14 | Gufic Biosciences Limited | | Mr. Pranav J Choksi | | Promoter, Chief Executive Officer & Whole Time Director | Any other transaction | Perquisites | | Approval of Audit Committee is not required | | | 0.20 | 0.00 | 0.00 | | | | | | | | | | |
| 15 | Gufic Biosciences Limited | | Mrs. Pooja P. Choksi | | Immediate Relative of Key Managerial Personnel | Any other transaction | Receiving of services | 9.50 | Approved | | | 4.75 | -0.71 | -0.71 | | | | | | | | | | |
| 16 | Gufic Biosciences Limited | | Mr. Pankaj J Gandhi | | Whole Time Director | Remuneration | | | Approval of Audit Committee is not required | | | 10.71 | 0.00 | 0.00 | | | | | | | | | | |
| 17 | Gufic Biosciences Limited | | Mr. Pankaj J Gandhi | | Whole Time Director | Any other transaction | Reimbursement of expenses paid | | Approval of Audit Committee is not required | | | 13.11 | 0.98 | -0.46 | | | | | | | | | | |
| 18 | Gufic Biosciences Limited | | Mr. Gopal M Daptari | | Independent Director (Upto 23.11.2024) | Any other transaction | Sitting fees | | Approval of Audit Committee is not required | | | 0.80 | -0.36 | 0.00 | | | | | | | | | | |
| 19 | Gufic Biosciences Limited | | Mr. Shreyas K Patel | | Independent Director (Upto 25.09.2024) | Any other transaction | Sitting fees | | Approval of Audit Committee is not required | | | 0.35 | 0.00 | 0.00 | | | | | | | | | | |
| 20 | Gufic Biosciences Limited | | Dr. Anu Aurora | | Independent Director | Any other transaction | Sitting fees | | Approval of Audit Committee is not required | | | 1.35 | 0.00 | 0.00 | | | | | | | | | | |
| 21 | Gufic Biosciences Limited | | Mr. Kamal Kishore Seth | | Independent Director | Any other transaction | Sitting fees | | Approval of Audit Committee is not required | | | 1.50 | 0.00 | 0.00 | | | | | | | | | | |
| 22 | Gufic Biosciences Limited | | Mr. Akshya Kumar Mahapatra | | Independent Director (Appointed w.e.f 14.11.2024) | Any other transaction | Sitting fees | | Approval of Audit Committee is not required | | | 1.05 | 0.00 | 0.00 | | | | | | | | | | |
| 23 | Gufic Biosciences Limited | | Veira Life FZE | | Wholly Owned Subsidiary of the Company | Any other transaction | Reimbursement of expenses received | 25.00 | Approved | | | 22.59 | 0.00 | 22.59 | | | | | | | | | | |
| **Total value of transaction during the reporting period** | | | | | | | | | | | | 507.59 | | | | | | | | | | | | |

Notes:
1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31.
Companies with financial years ending in other months, the six months period shall apply accordingly.
5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type.
However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
6. In case of a multi-year related party transaction:
a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
b. The value of the related party transaction ratified by the audit committee shall be disclosed in the column "Value of the related party transaction ratified by the audit committee".
c. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
7. "Cost" refers to the cost of borrowed funds for the listed entity. 8. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.